Giada Andrea Cassanmagnago

This study identifies miR-29 as a key regulator of age-related epigenetic changes, showing it promotes fidelity but reduces plasticity in methylome maintenance and adaptation.

This study identifies a SWI/SNF-targeting therapy effective against a double-negative prostate cancer subtype, showing it reduces viability in both AR-dependent and WNT-dependent models.

This study shows that loss of EHF promotes cell plasticity, transformation, and androgen independence in early prostate cancer by disrupting lineage integrity and activating downstream pathways.

This study shows that disrupting FOXA1 and FOXA2 disrupts oncogenic programs in both AR-positive and AR-negative prostate cancers.